Proteomics based evaluation of the antidiabetic activity of a polyherbal formulation in Streptozotocin-induced hyperglycemia in rats

Abstract

Proteomics have proven advantage in drug and disease physiology characterization. Here the polyherbal formulation was administered daily via oral gavage in two groups of Six Sprague Dawley diabetic rats at the doses of 250 mg/kg and 500 mg/kg body weight for 21 days to understand its antidiabetic potential with proteomics approach. Blood sugar levels were monitored weekly during experimentation. The concurrent control group receiving 10 mL/kg water was also maintained. Rats were examined regularly for signs of toxicity and mortality and underwent detailed clinical examinations prior to initiation and weekly thereafter. Body weight and food consumption were recorded weekly. The anti-hyperglycaemic effect of the formulation was estimated from blood glucose levels weekly. There was no observed mortality or adverse clinical signs among the rats exposed to the standard drug and formulation. Streptozotocin caused a significant weight loss in rats, while treatment with formulation at 250 and 500 mg/kg b.w. concentrations and Glibenclamide as a standard drug; restrained the decrease in body weight. The streptozotocin-induced diabetic rats exhibited a sharp elevation in blood glucose levels. The blood glucose levels were significantly lowered in a dose dependent manner post formulation treatment, in comparison to the control group. Treatment with formulation, standard, and streptozotocin did not induce any remarkable gross pathological alterations in any of the organs/tissues of rats. In proteomics analysis, in formulation treatment groups ECM and Circadian entrainment pathways were activated which are in line with the objective of normalization of altered metabolism in diabetes.